CHEK2 and breast carcinoma: No significant differences were observed between average age at breast cancer diagnosis for CHEK2 1100delC carriers compared to other CHEK2 pathogenic variants (63.7 ± 9.6 years; p = 0.09) or to men who did not test positive (p = 0.07), though these trended toward significance.